Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,083,842 shares, an increase of 3.8% from the October 13th total of 1,044,475 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 150,622 shares, the days-to-cover ratio is currently 7.2 days.
Hemispherx BioPharma (NYSEAMERICAN:HEB) opened at $0.32 on Wednesday. Hemispherx BioPharma has a 52 week low of $0.30 and a 52 week high of $0.94.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter. The company had revenue of $0.21 million for the quarter. Hemispherx BioPharma had a negative return on equity of 75.57% and a negative net margin of 1,029.58%.
A hedge fund recently raised its stake in Hemispherx BioPharma stock. Vanguard Group Inc. increased its position in Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) by 0.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 453,805 shares of the specialty pharmaceutical company’s stock after buying an additional 2,709 shares during the quarter. Vanguard Group Inc. owned about 1.56% of Hemispherx BioPharma worth $227,000 at the end of the most recent reporting period.
ILLEGAL ACTIVITY WARNING: “Hemispherx BioPharma, Inc (HEB) Short Interest Up 3.8% in October” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/15/hemispherx-biopharma-inc-heb-short-interest-up-3-8-in-october.html.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.